Table 2.
Medication according to the study group.
| CCS + DM N = 20 | CCS- DM N = 25 | Control group N = 21 | p-value | |
|---|---|---|---|---|
| Beta blockers, n (%) | 17 (85.0) | 20 (80.0) | 1 (4.8) | < 0.001 |
| ACEI/ARB, n (%) | 15 (75.0) | 16 (64.0) | 3 (14.3) | < 0.001 |
| Calcium channel blockers, n (%) | 9 (45.0) | 3 (12.0) | 0 | < 0.001 |
| Diuretics, n (%) | 3 (15.0) | 4 (16.0) | 0 | 0.157 |
| Acetylsalicyl acid, n (%) | 20 (100.0) | 25 (100) | 0 | < 0.001 |
| High-dose statins, n (%) | 20 (100.0) | 23 (92.0) | 0 | < 0.001 |
| Diabetes medication, n (%) | ||||
| Metformin | 19 (95.0) | 0 | 0 | |
| Sulfonylurea | 4 (20.0) | 0 | 0 | |
| Pioglitazone | 1 (5.0) | 0 | 0 | |
| SGLT2-inhibitors | 3 (15.0) | 0 | 0 | |
| GLP-1 RA | 1 (5.0) | 0 | 0 | |
| DPP-4- inhibitor | 6 (30.0) | 0 | 0 | |
| Insulin | 7 (35.0) | 0 | 0 | |
ACEI- angiotensin-converting enzyme inhibitors, ARB- angiotensin II receptor blockers, CCS- chronic coronary syndrome, DM2-diabetes mellitus type 2, DPP4- dipeptidyl peptidase 4, GLP1 RA- Glucagon-like peptide-1 receptor antagonist, IQR-interquartile range, SGLT2-sodium-glucose cotransporter-2, SD - standard deviation.
CCS + DM-subjects with a history of CCS and DM, CCS-DM- subjects with CCS but without DM2,. control group without CCS- control group.